Olaparib sebagai Terapi Metastatic-Castration Resistant Prostate Cancer (mCRPC): Systematic Review dan Meta Analysis”

Gunawan, I Made Rian and Herawati, Fauna and Kirtishanti, Aguslina (2024) Olaparib sebagai Terapi Metastatic-Castration Resistant Prostate Cancer (mCRPC): Systematic Review dan Meta Analysis”. Jurnal Farmasi Sains dan Terapan (Journal of Pharmacy Science and Practice), 11 (1). pp. 1-14. ISSN 2338-8404; eISSN 2657-2311 (Submitted)

PDF 3.b JFST 073 - LOA_I Made Rian Putra Gunawan.pdf Download (279kB)

Abstract

Prostate cancer is the second most prevalent cancer in men with approximately 1.4 million men worldwide. The main therapy for prostate cancer is androgen deprivation therapy (ADT), but patients who have received ADT may experience a condition of castration resistant prostate cancer (CRPC). More than 84% of patients have metastasized when diagnosed with CRPC (mCRPC) with the median survival of about 36 months. The Food & Drugs Association (FDA) has approved a new therapy for mCRPC patients, for example olaparib. The purpose of this systematic review and meta analysis was to assess the effectiveness (overall survival) and safety of olaparib in mCRPC. This research used randomized control trial’s (RCT) article. The literature search process was carried out using the PubMed database. The quality of article inclusion was assessed using the Critical Appraisal Skill Program (CASP) checklist and journal reputation. The results of the meta-analysis on the effectiveness of olaparib has showed that there was no significant difference in the patient's overall survival rate (RR=0. 81; 95% CI=0.58-1.13). The results of the meta analysis on the safety level of olaparib demonstrated a significant difference, observed on the side effects such as anemia (RR=3.47; 95% CI=2.59-4.65), nausea (RR=2.05; 95% CI=1.62-2.60) and fatigue (RR=1.32; 95% CI=1.10-1.59). The conclusion was olaparib as a mCRPC therapy did not show a significant effectiveness in improving the overall survival in mCRPC. In addition, the low safety level of olaparib in mCRPC patients was observed in the side effects such as anemia, nausea and fatigue.

Item Type:	Article
Uncontrolled Keywords:	PARP inhibitors; Olaparib; Overall Survival; Safety
Subjects:	R Medicine > RM Therapeutics. Pharmacology
Divisions:	Postgraduate Programs > Master Program in Clinical Pharmacy
Depositing User:	I Made Rian Putra Gunawan
Date Deposited:	22 Feb 2024 07:40
Last Modified:	22 Feb 2024 07:40
URI:	http://repository.ubaya.ac.id/id/eprint/46026

Actions (login required)

View Item